Paclitaxel (albumin bound)

DRUG3 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Affiliated Hospital of Guangdong Medical University

Conditions

Endometrial CarcinomaInoperable Locally Advanced HER2-Negative Breast CancerMetastatic HER2-Negative Breast CancerNasopharyngeal Carcinoma (NPC)Recurrent or MetastaticTP53 Mutation

Phase 1

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

RecruitingNCT06942234

Jiangsu Alphamab Biopharmaceuticals Co., LtdInoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer

Start: 2025-06-01End: 2027-12-31Target: 180Updated: 2025-09-17

Phase 2

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

RecruitingNCT06413992

Cancer Institute and Hospital, Chinese Academy of Medical SciencesEndometrial Carcinoma, Recurrent or Metastatic, TP53 Mutation

Start: 2024-05-10End: 2027-06-01Target: 117Updated: 2024-05-14

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Not yet recruitingNCT07136519

Affiliated Hospital of Guangdong Medical UniversityNasopharyngeal Carcinoma (NPC)

Start: 2025-08-22End: 2029-12-31Target: 30Updated: 2025-08-22